MSN Laboratories has launched JAK inhibitor molecules Tofacitinib (Tofadoz) and Upadacitinib (Upadoz) in India. This launch enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.

"The introduction of Upadoz reflects our commitment to bringing affordable bioequivalent medications to alleviate the suffering of Indian patients," said Dr MSN Reddy, Founder and CMD, MSN Group.

MSN Laboratories is committed to providing affordable medicines, having previously launched close to 50 first-time molecules in India. The company holds the No. 1 position in Active Pharmaceutical Ingredient (API) US DMF filings.

Bharat Reddy, Executive Director, MSN Group, added, "Autoimmune diseases are a growing public health issue, and the cost of treatment is substantial. This launch will make treatment more accessible to Indian patients."